Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2023-Global

Publisher Name :
Date: 31-Jan-2017
No. of pages: 128
Price : Single User: US $ 4950  US $ 3960 Corporate User: US $ 14850  US $ 8910
This report is available at 20% Discount for Single User License and 40% Discount for Corporate Users License till 31 December 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and market size of the CMV for theglobal, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for 2013-2023. It also includes global historical and forecasted epidemiological data for the CMV Prevalent, Diagnosed and Treatable Cases, CMV Patients among Transplants, Infants Patients at High Risk of CMV and HIV Patients at High Risk of CMVfrom 2013-2023. According to DelveInsight, the Global Diagnosed cases for Cytomegalovirus (CMV) Infection are expected to increase at a CAGR of 0.047% to 172,864 cases in 2023. Cytomegalovirus (CMV) infection is caused by Cytomegalovirus (CMV), a member of the herpes virus family. Upon initial infection, CMV infects the epithelial cells of the salivary gland, resulting in a persistent infection and viral shedding. Person can be infected with CMV at any point of time in life and is not easily diagnosed as no symptoms are shown.

As per DelveInsight's estimation, the global market size of Cytomegalovirus (CMV) infection shall reach to USD 1,210.4 Million by the end of 2023. The market size for Prophylaxis is expected to grow at a CAGR 6.57% from 2013-2023, while the sales for the therapeutic shall increase at a CAGR of 3.44% from the 2013-2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.

- Marketed information including available prescription drugs.

- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.

- It also provides Market size of Cytomegalovirus (CMV) infection for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.

This report is available at 20% Discount for Single User License and 40% Discount for Corporate Users License till 31 December 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2023-Global

Table of Contents

Cytomegalovirus Infections
Disease Overview
Symptoms of cytomegalovirus (CMV) Infection
Etiology
Risk Factors
Pathogenesis of human cytomegalovirus
Pathophysiology of cytomegalovirus infection
Diagnosis
Treatment Algorithm for Cytomegalovirus Infections
Treatment for Congenital CMV Infection
Treatment of Ganciclovir resistant CMV
Treatment Guidelines
Recommendations for Treating Cytomegalovirus Infections
Disease Management
Epidemiology and Patient Population
Global
Global CMV Prevalent, Diagnosed and Treatable Cases
United States
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Europe
Italy
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Spain
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
United Kingdom
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Germany
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
France
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infants Patients at High Risk of CMV
HIV Patients at High Risk of CMV
Japan
Assumptions and Rationale
Total CMV Prevalent, Diagnosed and Treatable Cases
CMV Patients among Transplants
Infant Patients at High Risk of CMV
HIV Patients at High Risk of CMV in Japan
Unmet Medical Needs
Marketed Products
Valcyte (Valganciclovir hydrochloride)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
FOSCAVIR (foscarnet sodium)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
CytoGam (Cytomegalovirus Immune Globulin Intravenous-Human)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
CytoTect CP
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
Valtrex (Valacyclovir hydrochloride)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
SWOT Analysis
Emerging Products Analysis
Emerging Therapies
1. Approved Products
Cytovir CMV: Cell Medica Ltd.
Product Description
Research and Development
Product Development Activities
2. Pipeline Products (Phase III)
CytoTect CP 70: Biotest AG.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Letermovir: Merck & Co.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Brincidofovir: Chimerix Inc.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
ASP0113: Astellas Pharma Global Development, Inc.
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Human Cytomegalovirus Immune Globulin: CSL Behring
Product Description
Advantages & Disadvantages
Research and Development
Product Development Activities
Global Market Size
United States
Europe
Italy
Germany
France
Spain
United Kingdom
Japan
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

List of Tables

Table 1: Total CMV Prevalent, Diagnosed and Treatable Cases (2013-2023)
Table 2: Total CMV Prevalent, Diagnosed and Treatable Cases for United States (2013-2023)
Table 3: CMV Patients among Transplants in United States (2013-2023)
Table 4: Infants Patients at High Risk of CMV in United States (2013-2023)
Table 5: HIV Patients at High Risk of CMV in United States (2013-2023)
Table 6 Total CMV Prevalent, Diagnosed and Treatable Cases for Italy (2013-2023)
Table 7: CMV Patients among Transplants in Italy (2013-2023)
Table 8: Infants Patients at High Risk of CMV in Italy (2013-2023)
Table 9: HIV Patients at High Risk of CMV in Italy (2013-2023)
Table 10: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain (2013-2023)
Table 11: CMV Patients among Transplants in Spain (2013-2023)
Table 12: Infants Patients at High Risk of CMV in Spain (2013-2023)
Table 13: HIV Patients at High Risk of CMV in Spain (2013-2023)
Table 14: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom (2013-2023)
Table 15: CMV Patients among Transplants in United Kingdom (2013-2023)
Table 16: Infants Patients at High Risk of CMV in United Kingdom (2013-2023)
Table 17: HIV Patients at High Risk of CMV in United Kingdom (2013-2023)
Table 18: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany (2013-2023)
Table 19: CMV Patients among Transplants in Germany (2013-2023)
Table 20: Infants Patients at High Risk of CMV in Germany (2013-2023)
Table 21: HIV Patients at High Risk of CMV in Germany (2013-2023)
Table 22: Total CMV Prevalent, Diagnosed and Treatable Cases for France (2013-2023)
Table 23: CMV Patients among Transplants in France (2013-2023)
Table 24: Infants Patients at High Risk of CMV in France (2013-2023)
Table 25: HIV Patients at High Risk of CMV in France (2013-2023)
Table 26: Total CMV Prevalent, Diagnosed and Treatable Cases for Japan (2013-2023)
Table 27: CMV Patients among Transplants in Japan (2013-2023)
Table 28: Infants Patients at High Risk of CMV in Japan (2013-2023)
Table 29: HIV Patients at High Risk of CMV in Japan (2013-2023)
Table 30: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 31: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 32: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 33: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 34: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 35: Total Market size of Cytomegalovirus (CMV) Infection USD, Million (2013-2023)
Table 36: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)
Table 37: Total Market size of Cytomegalovirus (CMV) Infection USD, Million(2013-2023)

List of Figures

Figure 1: Risk Factors CMV infection, 2017
Figure 2: Total CMV Prevalent, Diagnosed and Treatable Cases (2013-2023)
Figure 3: Total CMV Prevalent, Diagnosed and Treatable Cases for United States (2013-2023)
Figure 4: CMV Patients among Transplants in United States (2013-2023)
Figure 5: Infants Patients at High Risk of CMV in United States (2013-2023)
Figure 6: HIV Patients at High Risk of CMV in United States (2013-2023)
Figure 7: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy (2013-2023)
Figure 8: CMV Patients among Transplants in Italy (2013-2023)
Figure 9: Infants Patients at High Risk of CMV in Italy (2013-2023)
Figure 10: HIV Patients at High Risk of CMV in Italy (2013-2023)
Figure 11: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain (2013-2023)
Figure 12: CMV Patients among Transplants in Spain (2013-2023)
Figure 13: Infants Patients at High Risk of CMV in Spain (2013-2023)
Figure 14: HIV Patients at High Risk of CMV in Spain (2013-2023)
Figure 15: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom (2013-2023)
Figure 16: CMV Patients among Transplants in United Kingdom (2013-2023)
Figure 17: Infants Patients at High Risk of CMV in United Kingdom (2013-2023)
Figure 18: HIV Patients at High Risk of CMV in United Kingdom (2013-2023)
Figure 19: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany (2013-2023)
Figure 20: CMV Patients among Transplants in Germany (2013-2023)
Figure 21: Infants Patients at High Risk of CMV in Germany (2013-2023)
Figure 22: HIV Patients at High Risk of CMV in Germany (2013-2023)
Figure 23: Total CMV Prevalent, Diagnosed and Treatable Cases for France (2013-2023)
Figure 24: CMV Patients among Transplants in France (2013-2023)
Figure 25: Infants Patients at High Risk of CMV in France (2013-2023)
Figure 26: HIV Patients at High Risk of CMV in France (2013-2023)
Figure 27: Total CMV Prevalent, Diagnosed and Treatable Cases for Japan (2013-2023)
Figure 28: CMV Patients among Transplants in Japan (2013-2023)
Figure 29: Infants Patients at High Risk of CMV in Japan (2013-2023)
Figure 30: HIV Patients at High Risk of CMV in Japan (2013-2023)
Figure 31: Total Market Size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
Figure 32: US Market Size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
Figure 33: Italy market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
Figure 34: Germany market size of Cytomegalovirus (CMV) Infection in USD, Million (2013-2023)
Figure 35: France market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
Figure 36: Spain market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
Figure 37: UK market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
Figure 38: Japan market size of Cytomegalovirus (CMV) Infection in USD, Million(2013-2023)
  • United States Tigecycline Market Report 2017
    Published: 22-Nov-2017        Price: US 3800 Onwards        Pages: 105
    In this report, the United States Tigecycline market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Tige......
  • Global Tigecycline Sales Market Report 2017
    Published: 17-Nov-2017        Price: US 4000 Onwards        Pages: 118
    In this report, the global Tigecycline market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Tigecycline for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - South......
  • Global and Regional Cephalosporin Market Research Report 2017
    Published: 15-Nov-2017        Price: US 3500 Onwards        Pages: 180
    Summary Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections.Cephalosporin originally derived from the fungus Acremonium, which was previously known as ""Cephalosporium" Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South America - Middle East & Africa By Type - First Generation - Second Generation......
  • United States Cefprozil Market Report 2017
    Published: 15-Nov-2017        Price: US 3800 Onwards        Pages: 114
    In this report, the United States Cefprozil market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Cefpro......
  • Q Fever - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 36
    Q Fever - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Q Fever - Pipeline Review, H2 2017, provides an overview of the Q Fever (Infectious Disease) pipeline landscape. Q fever, also called query fever, is a bacterial infection caused by the bacteria Coxiella burnetii. Common symptoms of Q fever include high fever, cough, headache, diarrhea, nausea, abdominal pain, jaundice and muscl......
  • Escherichia coli Infections - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 171
    Escherichia coli Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H2 2017, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape. Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into cont......
  • Tularaemia - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 72
    Tularaemia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H2 2017, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape. Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conju......
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 84
    Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2017, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape. Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomyci......
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 369
    Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape. MRSA infections that are acquired by persons who have n......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs